Skip to content
Research peptides

GLOW Peptide Dosage: Vial Chart, Composition and Evidence

GLOW peptide dosage: the 70 mg vial split, reconstitution and daily dose reported by dosing sites, an injection-units chart, and what the evidence shows.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio

The short version

GLOW is a vendor-mixed vial of three research peptides - GHK-Cu, BPC-157 and TB-500 - sold as one product rather than three. No study, human or animal, has tested the three combined. Each ingredient has its own separate evidence base. This page covers what vendors say is in the vial, what that evidence shows, GLOW's legal status, and the dosing figures circulating online. No regulator or clinical trial has established any of them.

  • GLOW is a vendor-picked mix of three peptides, not a studied combination product.
  • No human or animal study has tested GHK-Cu, BPC-157 and TB-500 combined.
  • Two of its three ingredients are prohibited in sport at all times.
  • The dosing numbers below come from vendor and protocol sites, not a trial or regulator.

GLOW is a vendor-picked mixture of three peptides - GHK-Cu, BPC-157 and TB-500 - sold together in a single vial. The name reflects its skin and recovery focus. GHK-Cu has decades of cosmetic use and wound-healing research. BPC-157 and TB-500 both have animal tissue-repair studies behind them. I found no study, of any kind, that has tested the mixture.

This page covers what vendors say is in the vial, what the separate published evidence on each ingredient shows, GLOW’s legal status, and the dosing figures circulating online. No trial or regulator has established any of those figures.

What’s actually in the vial

Two research-chemical vendors selling GLOW list the same per-ingredient breakdown: BioLongevity Labs and Peptide Partners. A third, True Research Labs, sells the same three ingredients in a 70 mg vial but does not publish a per-ingredient split on its product page.

IngredientAmountShare of vial
GHK-Cu50 mg71.4%
BPC-15710 mg14.3%
TB-50010 mg14.3%
Total70 mg100%

All three describe it as a lyophilized (freeze-dried) powder in one vial, not three separately dosed peptides. Peptide Partners’ listing states that “by law, any form of bodily introduction of this product into humans or animals is strictly prohibited.” True Research Labs’ page says the product “is not intended for human consumption, therapeutic, or diagnostic use.”

Nobody selling GLOW represents it as a medicine, a supplement, or a reviewed skincare product, whatever the name implies.

No study has tested the three combined

I could not locate a published human or animal study of GHK-Cu, BPC-157 and TB-500 given together, at any dose, by any route. The closest published data point combines only two of the three. A rat Achilles tendon study Biçer 2026 - Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837., in the references below gave 32 rats BPC-157 alone, TB-500 alone, or both together. The doses were 10 mcg/kg/day BPC-157 and 60 mcg/kg/day TB-500, intraperitoneally, for four weeks. The combined arm did not outperform TB-500 alone on biomechanical strength or histopathology. The paper reports no added benefit from combining the two.

What the evidence says about each ingredient

Each component has its own, separate literature. Putting three peptides in one vial does not merge their evidence.

  • GHK-Cu is the majority of the vial by weight (71.4%). My copper peptides guide covers it in full. It is a legal cosmetic ingredient with decades of use and a real research history in wound healing. The human evidence for the bigger anti-ageing claims is limited, and a randomized human trial of topical GHK-Cu indexed in PubMed was negative on its objective endpoints.
  • BPC-157 has a large, consistently positive animal literature on tissue healing, covered in my BPC-157 guide. The human evidence is small. No BPC-157 study is indexed in PubMed as a clinical trial. The published human experience totals roughly 80 people across five small studies, and the only randomized placebo-controlled one was never published beyond a meeting abstract.
  • TB-500: my TB-500 guide reports that I could not locate a single completed, published human randomized trial, for any indication. Much of the tissue-repair literature people cite for it studied full-length thymosin beta-4, a different molecule. A recent rat tendon study using TB-500 by name was positive.

GLOW’s status is mixed because it is a mix:

  • GHK-Cu is a legal cosmetic ingredient in the US and Australia - see the copper peptides guide for detail.
  • BPC-157 is not FDA-approved, sold as a research chemical, and prohibited at all times in sport under WADA’s Non-Approved Substances category - see the BPC-157 guide.
  • TB-500 is not FDA-approved, sold as a research chemical, and prohibited at all times in sport as a thymosin beta-4 derivative - see the TB-500 guide.

Every vendor selling the combined vial states it is not for human or animal use. That includes True Research Labs, BioLongevity Labs and Peptide Partners. That is a research-chemical-industry disclaimer, not a legal opinion about what buyers do with the product.

The vendors I check that sell GLOW, with dated prices and the split on each label: where to buy GLOW.

GLOW dosage chart: what’s circulating, not what’s established

No study or regulator has established a GLOW dose, because nobody has published a trial of the three-peptide combination. Two independent dosing sites describe the same common protocol for the 70 mg vial: Peptide Dosing Protocols and SeekPeptides. It is not a research finding and not a recommendation from this site.

Both describe reconstituting the 70 mg vial with 3.0 mL of bacteriostatic water, which gives about 23.3 mg/mL of total blend. Both describe a once-daily subcutaneous injection of 10 units on a U-100 insulin syringe (0.10 mL, about 2.33 mg total blend). That breaks down as roughly 1.67 mg GHK-Cu, 0.33 mg BPC-157 and 0.33 mg TB-500 per injection.

Peptide Dosing Protocols describes a typical cycle of “4-6 weeks” on and “2-4 weeks” off, noting that “GHK-Cu typically governs cycle length because of copper-handling considerations.” The chart below gives the units for that vial at the sourced 2.33 mg daily dose.

GLOW (GHK-Cu/BPC-157/TB-500) 70 mg vial

Water addedConcentration1 unit =2.33 mg
3 mL water23.33 mg/mL233.33 mcg10 units

Units on a U-100 insulin syringe (100 units = 1 mL), to the nearest half unit. 2.33 mg is the common once-daily dose reported by two independent dosing sites for a 70 mg vial in 3.0 mL water.

Reconstitution and injection volume

The figures above give approximate draw volumes for the specific 70 mg / 3.0 mL preparation that two dosing sites report. For any other vial size or dilution, use the dosage calculator. It works out concentration and draw volume. It performs the math; it does not tell you what amount to target.

Who should not use it

No FDA-reviewed contraindication list exists for GLOW, or for BPC-157 or TB-500 individually, because neither has gone through that review. There is no human safety data on the ingredients combined, and thin-to-zero human data on them separately (see above). Anyone pregnant, breastfeeding, immunocompromised, on other medications, or with a diagnosed medical condition has no regulator-reviewed information to weigh a decision against.

Risks

A multi-peptide vial carries risks specific to blending, beyond each ingredient’s own risks:

  • No vendor-published third-party testing confirms the finished mixture contains all three components at the labeled ratio.
  • An injection-site or systemic reaction could come from any one ingredient or an interaction between them, with no way to isolate which.
  • FDA has separately flagged possible immunogenicity concerns and unresolved impurity questions for compounds in this class.

Material sold as GLOW is a research chemical with no regulator-verified purity, identity or concentration.

Common questions

What is GLOW?

GLOW is a vendor name for a lyophilized powder blend of three peptides in one vial: GHK-Cu, BPC-157 and TB-500. The most common split is 50 mg, 10 mg and 10 mg respectively, for 70 mg total. Multiple research-chemical vendors sell it as research-use-only material, not as a product approved or reviewed for human use.

What is the GLOW peptide dosage?

There is no established human dose, because no study of the three-peptide combination exists. Two dosing-protocol sites independently describe the same figure. A 70 mg vial is reconstituted with 3.0 mL of bacteriostatic water and dosed once daily as 10 units (about 2.33 mg of total blend) on a U-100 insulin syringe. The dosage chart below gives the units for that vial. These are not clinical findings and not a recommendation.

Has GLOW been tested in any study?

No. I could not find a published human or animal study of GHK-Cu, BPC-157 and TB-500 combined. The closest published data point is a rat tendon study that combined two of the three ingredients, BPC-157 and TB-500. The combination performed no better than either one alone.

Is GLOW legal?

GLOW's status is mixed because it is a mix. GHK-Cu is a legal cosmetic ingredient in the US and Australia. BPC-157 and TB-500 are not FDA-approved and are sold as research chemicals, not legally marketed for human use. Every vendor selling the combined vial states it is for laboratory research only, not for human or animal consumption.

Is GLOW banned in sports?

Two of its three ingredients are. BPC-157 is prohibited at all times under WADA's Non-Approved Substances category, and TB-500 is prohibited at all times as a thymosin beta-4 derivative. GHK-Cu does not appear on the WADA list.

What are the risks of GLOW?

A multi-peptide vial adds risks specific to blending, on top of the risks of each ingredient. No vendor-published testing confirms the finished mixture at the stated ratio. Injection-site reactions could come from any one component or their interaction. Nothing about combining them has been studied for safety. FDA has separately flagged immunogenicity and impurity concerns for compounds in this class.

Who should not use GLOW?

No FDA-reviewed contraindication list exists for GLOW or for BPC-157 and TB-500 individually. There is no human safety data on the combination. Anyone pregnant, breastfeeding, immunocompromised, on other medications, or with a diagnosed medical condition has no regulator-reviewed information to weigh a decision against.

How often do you inject GLOW peptides?

No study or regulator has set a schedule. Two dosing sites describe a common practice, not an established dose. It is one subcutaneous injection a day (10 units from a 70 mg vial mixed with 3.0 mL of bacteriostatic water). One of them describes cycles of 4-6 weeks on and 2-4 weeks off. GLOW is sold for research use only; see the dosage chart below.

What are the cons of GLOW peptides?

I found no study of the three-peptide combination in any species. The one test of two of its ingredients together, in rats, found no added benefit over TB-500 alone. GLOW is sold for research use only with no verified purity or mix ratio. BPC-157 and TB-500 have little or no human trial data, and both are banned in sport at all times.

Does GLOW peptide help with fat loss?

I found no evidence that it does. I found no study of GLOW for anything, fat loss included. The ingredient evidence summarised on this page concerns tissue repair, wound healing and skin, not body fat. It is sold for research use only, not as a weight-loss product reviewed by any regulator.

References (7 sources)

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

  1. 1.Biçer O, Adanir O, Güleryüz Y et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837.StudyPMID 42542926
  2. 2.True Research Labs - GLOW Blend product page, listing BPC-157, TB-500 and GHK-Cu and stating the product is for laboratory research use only, not for human or animal consumption.- True Research Labsother
  3. 3.BioLongevity Labs - GLOW Blend product page, stating 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 per 70 mg vial, research use only.- BioLongevity Labsother
  4. 4.Peptide Partners - GLOW Blend product page, stating the same 50/10/10 mg composition and a research-use-only, not-for-bodily-introduction disclaimer.- Peptide Partnersother
  5. 5.Peptide Dosing Protocols - GLOW stack page, a circulating community protocol with reconstitution and dosing figures, not a clinical or regulatory source.- peptidedosingprotocols.comother
  6. 6.SeekPeptides - GLOW peptide dosage guide, independently stating the same 3.0 mL reconstitution of a 70 mg vial and a once-daily 2.33 mg (10-unit) dose.- SeekPeptidesother
  7. 7.America's Poison Centers - home page, confirming the national Poison Control number 1-800-222-1222.- America's Poison Centersother

Keep reading

Related guides